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Philip C BigginPhil Biggin, PhD, is a group leader in the Department of
Biochemistry, University of Oxford. He is interested in
computational approaches to receptor dynamics and
ligand-binding. His group uses a wide range of method-
ologies ranging from molecular dynamics simulations
through to machine learning techniques to address fun-
damental problems in pharmacology. He is the Section
Editor for Computational, in silico and modelling studies
for BMC Pharmacology and Toxicology. In this interview
we find out a little more about the key issues in this field
of research.
How did you first become interested in
pharmacology and toxicology?
I became interested in chemistry and computers as a teen-
ager which led to my decision to read Computer-aided
Chemistry for my first degree. During that time I spent a
fascinating industrial year at SmithKline Beecham (now
GSK) developing software to aid the computational chem-
istry group. Although at that time I did not know I wanted
to do a PhD, I did know that I wanted to continue investi-
gating the way in which drugs work. I then undertook a
PhD in the biophysics of ion channels, which helped fill in
some of the biological gaps in my knowledge. The rest is
history as they say.
Why is it an exciting time to be involved with
computational aspects of pharmacology and
toxicology in particular?
Computational chemistry and molecular modelling have
been embedded within the drug-design process for many
years now and indeed most pharmaceutical companies
have some kind of computational chemistry group within
their Research and Development programmes. From early
quantitative structure activity relationship (QSAR) studies
and visualization through to cheminformatics andCorrespondence: philip.biggin@bioch.ox.ac.uk
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reproduction in any medium, provided the ormolecular dynamics, the scope and power of these techni-
ques is ever increasing and they are starting to yield im-
portant results that are not only interestingly academically,
but can result in substantial financial savings for drug
companies.
What challenges and developments can we
expect to see in the next few years?
One of the major challenges for computational chemists
remains the prediction of affinity for small molecules
with protein (and nucleic acid) targets. There have been
many approaches to this ranging from thermodynamic-
ally rigorous free energy calculations through to machine
learning methods. Although there have been examples
of good success, the prediction of absolute affinities
remains a major challenge for the field. If the prediction
of affinity was not challenging enough, the next problem
will be the prediction of efficacy. Just because a com-
pound binds with high affinity does not necessarily mean
it has high efficacy. In fact the problem may be even
worse than that, because it is becoming apparent that
some systems exhibit 'agonist bias' whereby the efficacy
of the same agonist is not maintained across different
pathways as discussed by Terry Kenakin in his review
article on this topic [1]. These aspects will be particu-
larly challenging because efficacy and agonist bias will
encompass the dynamic behaviour of the protein in re-
sponse to the ligand-binding event.
How can computational modelling contribute to
meeting these challenges?
Both of the problems above will become more tractable
with physical models as the computational power avail-
able increases. In fact, it is already possible to explore
timescales that are not only experimentally relevant but
also able to address problems that are difficult if not im-
possible to address by experiment alone [2]. We can cer-
tainly expect to see a closer link between computational
and experimental studies in that regard.his is an Open Access article distributed under the terms of the Creative
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prediction of adverse drug reactions?
Many of the challenges we face are still at the one
protein-one drug level, but in order to predict pharma-
cology and toxicology in the future effectively, more
consideration will have to be given to absorption, distri-
bution, metabolism, excretion and toxicity (ADMET).
Many adverse drug reactions are caused by unintended
activity at off-targets. There has been some recent suc-
cess in those types of predictions [3], and although
experiments are still needed to verify the results, the
predictions are useful enough to draw attention to pos-
sible problems earlier in the drug-discovery process, thus
saving money. One might also expect protein structure
and dynamics to play an increasing role in the prediction
of ADMET properties [4] as it is quite often the case
that off-target proteins have large flexible binding pock-
ets, something, which until recently, has largely been
ignored.
Is there a role for computational modelling in the
regulatory assessment of novel chemical entities?
The best predictions will be those that account for all of
the effects of a compound within the body and to that
end aspects of systems biology will certainly have a key
role to play. Indeed, physiologically based pharmacoki-
netic (PBPK) modelling is already used to guide the
decision-making process within regulatory review [5].
One might expect these kinds of models to be integrated
with pharmacogenetics studies to make further improve-
ments in the coming years.
What does the future hold for computational
pharmacology and what do you think are its
limitations?
The quality of future predictions will be underpinned by
two main factors: 1) Knowledge or data and 2) comput-
ing power. As both of those are rising exponentially, one
can look forward to more accurate computational
pharmacology sooner rather than later.
Are there any particular papers you would like to
see submitted to your section?
In keeping with the journal ethos to publish work
deemed by peer review to be a coherent and sound
addition to scientific knowledge I would be particularly
interested in seeing papers on drug interactions with
other macromolecular systems, especially those that are
supported by experimental data and shed light on the
underlying mechanism. Of course, that is a slightly per-
sonal view and we really would welcome submissions
from across the whole field of Computational, in silico
and modelling studies.Competing interests
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